Skip to main content

Table 2 Peritoneal Disease observed after cisplatin or cisplatin@CB[7] treatment. Pathological observations of the i.p. tumours extracted from the control, cisplatin and cisplatin@CB[7] groups. Size of tumour was determined as follows: + < 0.5 cm; ++ >0.5 cm < 1 cm; +++ >1 cm in diameter. Dissem. D. = Disseminated disease was determined as >3 small tumours spreaded throughout the peritoneal cavity

From: Cucurbit [7] uril encapsulated cisplatin overcomes resistance to cisplatin induced by Rab25 overexpression in an intraperitoneal ovarian cancer model

Treatment Dissem. Disease Attached to organ Size of Tumours Tumour for H&E % of Necrotic Area
Control 6/6 4/6 + 3/6 11.66 ± 8.924 %
Cisplatin i.p. 3/6 3/6 ++ 4/6 32 ± 6.75 %
Cisplatin@CB[7) i.p. 2/6 4/6 +++ 6/6 47.85 ± 10.11 %
Cisplatin@CB[7) s.c. 0/5 5/5 +++ 4/5 47.5 ± 18.35 %